# Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer

> **NCT03498326** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 480 (estimated)

## Conditions studied

- Pancreatic Cancer
- Chemotherapy Effect

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03498326
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-04-02
- **Primary completion:** 2023-03-31
- **Final completion:** 2030-03-31
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2018-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03498326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03498326, "Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03498326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*